# US 2019/0166897 A1 · Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rotavirus-associated diarrhoea > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0166897 A1 - Document ID: US20190166897A1 - Status: Published application - Kind: A1 - Application number: 16/321,279 - Filed: 2017-07-06 - Published: 2019-06-06 - Earliest claimed: 2016-08-04 - Assignees: Nestec S.A. - Applicants: Nestec S.A. - Inventors: Bernard Berger; Harald Bruessow - Web page: https://patentgrep.com/patent/US20190166897A1 ## CPC - A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics - A23L 33/21: Addition of substantially indigestible substances, e.g. dietary fibres - A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula} - A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages - A61K 31/733: Fructosans, e.g. inulin - A61K 35/745: Bifidobacteria - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/12: Antidiarrhoeals - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A23V 2200/3202: Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora - A23V 2200/3204: Probiotics, living bacteria to be ingested for action in the digestive tract - A23V 2250/284: Oligosaccharides, non digestible - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION ## Abstract The invention relates to a nutritional composition comprising at least one N-acetylated oligosaccharide, and at least one galacto-oligosaccharide, and at least one sialylated oligosaccharide. The composition optionally comprises a Bifidobacterium animalis spp. lactis probiotic, preferably CNCM-I-3446 probiotic. The composition treat ro reduces the risk, the severity and/or the occurrence of non-rotavirus associated diarrhoea. The composition also promotes a healthy intestinal flora and has beneficial long and short terms effects. The composition is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. ## Claims ### Claim 1 A method for preventing and/or treating and/or reducing the severity and/or risk and/or occurrence of non-rotavirus-associated diarrhea in infants or young children between 0 and 36 months comprising administering a nutritional composition for to infants or young children, the composition comprising at least one N-acetylated oligosaccharide, at least one galacto-oligosaccharide, and at least one sialylated oligosaccharide. ### Claim 2 (depends on 1) The method of claim 1 wherein the composition comprises a Bifidobacterium animalis spp. lactis probiotic, in an amount of between 105 and 1012 cfu per gram of composition. ### Claim 3 (depends on 1) The method of claim 1 for promoting or inducing a gut microbiota that is closer to the microbiota of infants fed exclusively with human breast milk, in comparison to the microbiota of infants fed predominantly with a conventional nutritional composition not comprising said probiotic, in infants or young children between 0 and 36 months, optionally between 0 and 12 months of age. ### Claim 4 (depends on 1) The method of claim 1 wherein the infants are born with a fragile or unbalanced microbiota or dysbiosis of microbiota. ### Claim 5 (depends on 1) The method of claim 1 wherein the composition comprises oligofructose. ### Claim 6 (depends on 1) The method of claim 1 wherein the composition comprising fat and at least 8%, preferably at least 9.6% of the fat is sn2 palmitate. ### Claim 7 (depends on 1) The method of claim 1 wherein the composition comprises triglycerides having more than 33% of the palmitic acid in sn2 position. ### Claim 8 (depends on 1) The method of claim 1 wherein the composition is an infant formula or a follow-on formula. ### Claim 9 (depends on 1) The method of claim 1 wherein the composition comprises alpha-lactalbumin proteins in an amount of at least 0.3 g/100 kcal or 2.3 g/L of composition. ### Claim 10 (depends on 3) The method of claim 3 in that the promoting or inducing a gut microbiota that is closer to infants fed exclusively with human breast milk is further characterized by comprising an up-regulation of the population of B. animalis and/or Bifidobacterium, and/or B. Longum and/or Lactobacillus, and/or a down regulation of the populations of Coprobacillus and/or Streptococcus. ### Claim 11 (depends on 3) The method of claim 3 wherein the promoting or inducing a gut microbiota that is closer to the microbiota of infants fed exclusively with human breast milk is further characterized by promoting or inducing a gut microflora that has a phylogenetic distance to the microbiota of breast fed infants of less than 0.3 units (measured by Unifrac method). ### Claim 12 (depends on 3) The method of claim 3 wherein the promoting and/or inducing a gut microbiota that is closer to infants fed exclusively with human breast milk is measurable in infants stools, optionally. ### Claim 13 (depends on 1) The method of claim 1 wherein the composition is fed during the first 12 weeks of life. ### Claim 14 (canceled) ### Claim 15 (depends on 1) The method of claim 1 wherein the composition comprises: N-acetylated oligosaccharides between 0.001 to 1 wt %; Galacto-oligosaccharides between 1 and 10 wt %; and Sialylated oligosaccharides between 0.005 and 1 wt %, all calculated as wt % of the composition.